Navigation Links
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
Date:2/26/2009

e patients receiving second-line therapies generally have a poorer prognosis than patients in the first-line setting."

About the Report

Renal Cell Carcinoma (Metastatic): Axitinib's Improvements in Overall Survival will Differentiate it from Current and Emerging Therapies is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2
'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
2. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
3. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
4. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
5. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
6. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
7. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Milestone Scientific Inc. (OTCQB: MLSS), the recognized leader in ... its 2010 year-end results for the 12 months ended ... Commission on Wednesday, March 30, 2011. Milestone,s ... 4, 2011 beginning at 4:15 PM Eastern Daylight Savings ...
... YORK, April 1, 2011 NeoStem, Inc. (NYSE Amex: ... company with operations in the U.S. and China, is today ... activities: Revenues for the year ended December ... 2009.  2010 was the first full year that results for ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2NeoStem Provides Results for 2010 and an Update on Recent Activities 2NeoStem Provides Results for 2010 and an Update on Recent Activities 3NeoStem Provides Results for 2010 and an Update on Recent Activities 4NeoStem Provides Results for 2010 and an Update on Recent Activities 5
(Date:5/24/2015)... May 24, 2015 EnviroLeather™ by ... “InkGard™ Plus” – a classic, rugged leather grain ... allowing difficult stains, including ink, to be easily ... colors suitable for corporate, healthcare, hospitality and education ... with EnviroLeather’s goal of developing products that are ...
(Date:5/24/2015)... Viejo, CA (PRWEB) May 24, 2015 ProPin ... use in Final Cut Pro X. Utilize ProPin to pin ... in a given scene. , ProPin allows users to ... completely customizable in FCPX. With on-screen controls, video editors can ... allows users to pin and mark with absolute ease. , Using ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Krihak as its head of programmatic strategy and ... expertise and leadership position in the data driven ... , Krihak is an experienced, award-winning agency and ... sales planning teams for mobile platform Jumptap. ...
(Date:5/24/2015)... 24, 2015 A report out ... the single best option for avoiding cardiovascular disease is ... level was the single most powerful predictor of death ... as diabetes and family history of premature death -- ... heart and lung fitness. , The Importance of Cardiovascular ...
(Date:5/23/2015)... D.C. (PRWEB) May 23, 2015 On ... of powers of a youngster's yogic power learned through ... Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, a ... more than 50 high profile professionals attending the 2015 ... by reading fluently -- blindfolded. , In a ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... 2009, Cambridge, UK ,Anyone with a sweet tooth knows ... negative consequences. The same can be said about the ... new study of myelin, a protein key to efficient neuronal ... much like the insulation on a cable, allows for rapid ...
... nanospheres equipped with a targeting peptide find melanoma cells, penetrate ... near-infrared light, a research team led by scientists at The ... the Feb. 1 issue of Clinical Cancer Research . ... grail of therapeutic nanotechnology for cancer. We,re getting closer to ...
... Knowing what to expect before and after procedure aids healing, ... With increasing numbers of baby boomers reaching retirement age, joint ... , But improved movement and lack of pain in ... to expect from the surgery and subsequent physical therapy can ...
... Total Health Center shows that our new Hgh product destroys fat cells ... , ... (PRWEB) February 1, 2009 -- Scientists at The Total Health and ... to destroy fat on men and women without dieting. Sources at the ...
... A study in the Feb. 1 issue of the ... levels that occurs during pregnancy is more pronounced in pregnant ... , During the last trimester of pregnancy, levels ... women with RLS and 25,475 pg/mL in healthy controls. ...
... A study in the Feb. 1 issue of the ... associated with changes in the levels of specific cytokines ... suggest that inflammation may be the pathway linking extreme ... Each additional hour of self-reported sleep duration was associated ...
Cached Medicine News:Health News:Targeted nanospheres find, penetrate, then fuel burning of melanoma 2Health News:Targeted nanospheres find, penetrate, then fuel burning of melanoma 3Health News:A Checklist for Joint Replacement Surgery 2Health News:Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome 2Health News:Study suggests that inflammation may be the link between extreme sleep durations and poor health 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: